Lao-Tzu S. Allan-Blitz, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gonorrhea | 15 | 2023 | 335 | 5.970 |
Why?
|
| Neisseria gonorrhoeae | 15 | 2023 | 238 | 5.740 |
Why?
|
| Ciprofloxacin | 12 | 2023 | 313 | 4.110 |
Why?
|
| DNA Gyrase | 8 | 2023 | 82 | 3.440 |
Why?
|
| Sexually Transmitted Diseases | 5 | 2023 | 616 | 2.700 |
Why?
|
| Drug Resistance, Bacterial | 12 | 2023 | 1030 | 1.990 |
Why?
|
| Syphilis | 4 | 2019 | 225 | 1.810 |
Why?
|
| Homosexuality, Male | 8 | 2023 | 1239 | 1.800 |
Why?
|
| Microbial Sensitivity Tests | 10 | 2023 | 1865 | 1.640 |
Why?
|
| Chlamydia Infections | 3 | 2021 | 364 | 1.540 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 2022 | 24 | 1.500 |
Why?
|
| Anti-Bacterial Agents | 15 | 2023 | 7134 | 1.470 |
Why?
|
| Pharynx | 3 | 2018 | 411 | 1.110 |
Why?
|
| Anal Canal | 2 | 2017 | 373 | 0.970 |
Why?
|
| Los Angeles | 7 | 2021 | 236 | 0.960 |
Why?
|
| HIV Infections | 10 | 2023 | 16763 | 0.950 |
Why?
|
| Sexual Partners | 4 | 2023 | 727 | 0.910 |
Why?
|
| Sexual Behavior | 6 | 2023 | 2040 | 0.880 |
Why?
|
| Monkeypox virus | 1 | 2022 | 47 | 0.870 |
Why?
|
| Syphilis Serodiagnosis | 2 | 2019 | 35 | 0.830 |
Why?
|
| Azithromycin | 2 | 2018 | 194 | 0.730 |
Why?
|
| Proctitis | 1 | 2019 | 40 | 0.690 |
Why?
|
| Mycoplasma genitalium | 1 | 2018 | 10 | 0.670 |
Why?
|
| Sex Offenses | 1 | 2023 | 347 | 0.650 |
Why?
|
| Mycoplasma Infections | 1 | 2018 | 118 | 0.650 |
Why?
|
| Asymptomatic Infections | 1 | 2019 | 129 | 0.650 |
Why?
|
| Prisoners | 1 | 2021 | 297 | 0.640 |
Why?
|
| Medical History Taking | 1 | 2022 | 782 | 0.640 |
Why?
|
| Coxiella burnetii | 1 | 2018 | 37 | 0.630 |
Why?
|
| Q Fever | 1 | 2018 | 37 | 0.630 |
Why?
|
| AIDS Serodiagnosis | 1 | 2019 | 202 | 0.620 |
Why?
|
| Meningitis, Bacterial | 1 | 2018 | 216 | 0.560 |
Why?
|
| Peru | 5 | 2023 | 879 | 0.550 |
Why?
|
| Epidemics | 1 | 2021 | 520 | 0.530 |
Why?
|
| Genotype | 6 | 2019 | 12950 | 0.520 |
Why?
|
| Immunoassay | 1 | 2018 | 750 | 0.500 |
Why?
|
| Ceftriaxone | 3 | 2022 | 167 | 0.490 |
Why?
|
| Endocarditis, Bacterial | 1 | 2018 | 453 | 0.480 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 2241 | 0.450 |
Why?
|
| Cefixime | 2 | 2022 | 12 | 0.410 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 4400 | 0.400 |
Why?
|
| California | 3 | 2021 | 1400 | 0.380 |
Why?
|
| Florida | 2 | 2022 | 437 | 0.380 |
Why?
|
| Seroepidemiologic Studies | 2 | 2021 | 401 | 0.360 |
Why?
|
| Humans | 45 | 2023 | 739219 | 0.350 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 1175 | 0.350 |
Why?
|
| Cities | 2 | 2022 | 512 | 0.350 |
Why?
|
| Poverty | 1 | 2021 | 2626 | 0.340 |
Why?
|
| Prevalence | 8 | 2021 | 15152 | 0.330 |
Why?
|
| Pediatrics | 1 | 2022 | 3454 | 0.300 |
Why?
|
| Health Promotion | 1 | 2019 | 2187 | 0.300 |
Why?
|
| Unsafe Sex | 2 | 2019 | 220 | 0.290 |
Why?
|
| Polymerase Chain Reaction | 3 | 2022 | 6176 | 0.290 |
Why?
|
| Chlamydia trachomatis | 2 | 2017 | 246 | 0.260 |
Why?
|
| Pandemics | 2 | 2021 | 8274 | 0.240 |
Why?
|
| Rectum | 2 | 2019 | 899 | 0.240 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2023 | 59 | 0.230 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3051 | 0.230 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 1779 | 0.230 |
Why?
|
| Leukotriene E4 | 1 | 2023 | 79 | 0.220 |
Why?
|
| Antibodies, Bacterial | 2 | 2018 | 1465 | 0.210 |
Why?
|
| Mass Screening | 4 | 2019 | 5265 | 0.210 |
Why?
|
| Adult | 13 | 2023 | 213375 | 0.180 |
Why?
|
| New York City | 1 | 2021 | 704 | 0.170 |
Why?
|
| Young Adult | 7 | 2023 | 56252 | 0.170 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2019 | 200 | 0.170 |
Why?
|
| Male | 16 | 2023 | 348967 | 0.170 |
Why?
|
| Female | 16 | 2023 | 378808 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 1 | 2023 | 388 | 0.160 |
Why?
|
| Long-Term Care | 1 | 2022 | 606 | 0.160 |
Why?
|
| Saliva | 1 | 2022 | 805 | 0.160 |
Why?
|
| Cytokines | 2 | 2023 | 7296 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 549 | 0.160 |
Why?
|
| Mentors | 1 | 2022 | 632 | 0.150 |
Why?
|
| Hepatitis B | 1 | 2023 | 688 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2023 | 865 | 0.150 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2018 | 230 | 0.150 |
Why?
|
| Antigens, Viral | 1 | 2021 | 1036 | 0.150 |
Why?
|
| Microbiological Techniques | 1 | 2017 | 101 | 0.150 |
Why?
|
| Doxycycline | 1 | 2018 | 327 | 0.140 |
Why?
|
| RNA, Bacterial | 1 | 2018 | 393 | 0.140 |
Why?
|
| Demography | 1 | 2021 | 1650 | 0.140 |
Why?
|
| Cephalosporins | 1 | 2017 | 204 | 0.140 |
Why?
|
| Macrolides | 1 | 2017 | 199 | 0.130 |
Why?
|
| Codon | 1 | 2017 | 613 | 0.130 |
Why?
|
| Fluoroquinolones | 1 | 2017 | 306 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 946 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2023 | 3193 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 14721 | 0.120 |
Why?
|
| Hydroxychloroquine | 1 | 2018 | 407 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2018 | 591 | 0.120 |
Why?
|
| Transsexualism | 1 | 2017 | 173 | 0.120 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 24711 | 0.120 |
Why?
|
| Employment | 1 | 2021 | 1119 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 1847 | 0.120 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 329 | 0.110 |
Why?
|
| Social Stigma | 1 | 2019 | 695 | 0.110 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 1467 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 1537 | 0.110 |
Why?
|
| Adolescent | 5 | 2021 | 85409 | 0.110 |
Why?
|
| Medical Records | 1 | 2018 | 1413 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2021 | 40385 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 1675 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2023 | 76632 | 0.100 |
Why?
|
| HIV Antibodies | 1 | 2018 | 1309 | 0.100 |
Why?
|
| Incidence | 2 | 2021 | 20912 | 0.100 |
Why?
|
| Colonoscopy | 1 | 2019 | 1363 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2017 | 1181 | 0.100 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 607 | 0.090 |
Why?
|
| HIV | 1 | 2017 | 1607 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2021 | 1891 | 0.090 |
Why?
|
| Curriculum | 1 | 2022 | 3575 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 6478 | 0.090 |
Why?
|
| Vaccination | 1 | 2021 | 3232 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 973 | 0.080 |
Why?
|
| Scoliosis | 1 | 2015 | 720 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2021 | 2491 | 0.080 |
Why?
|
| Public Health | 1 | 2021 | 2587 | 0.080 |
Why?
|
| United States | 3 | 2021 | 69568 | 0.070 |
Why?
|
| Mutation | 4 | 2023 | 29659 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 4521 | 0.070 |
Why?
|
| Internet | 1 | 2018 | 3048 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 3863 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18347 | 0.060 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 4320 | 0.060 |
Why?
|
| Child | 2 | 2022 | 77029 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2023 | 25470 | 0.060 |
Why?
|
| Risk Factors | 2 | 2021 | 71972 | 0.060 |
Why?
|
| Sierra Leone | 1 | 2023 | 166 | 0.050 |
Why?
|
| Middle Aged | 5 | 2021 | 212833 | 0.050 |
Why?
|
| Genitalia | 1 | 2023 | 111 | 0.050 |
Why?
|
| Hospitals, Public | 1 | 2023 | 204 | 0.050 |
Why?
|
| Genomics | 1 | 2017 | 5655 | 0.050 |
Why?
|
| Serine-Type D-Ala-D-Ala Carboxypeptidase | 1 | 2019 | 20 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 510 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 469 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 53036 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 1837 | 0.030 |
Why?
|
| Rural Population | 1 | 2023 | 2181 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 1262 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 162667 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 7789 | 0.020 |
Why?
|